View Older Stories View More Recent Stories

Jun 1, 2023 04:20PM LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
Jun 1, 2023 08:09AM LAVA Therapeutics to Participate in the Jefferies Healthcare Conference
May 30, 2023 05:28PM LAVA Announces Annual Meeting of Shareholders
Apr 11, 2023 07:00AM LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
Mar 9, 2023 08:07AM LAVA Therapeutics (LVTX) Announces Appointment of Christy J. Oliger to its Board of Directors
Mar 9, 2023 08:05AM LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors
Feb 16, 2023 07:01AM LAVA Therapeutics (LVTX) Announces Initial Data from Ongoing Phase 1/2a Trial of LAVA-1207
Feb 16, 2023 07:00AM LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
Feb 9, 2023 07:00AM LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference
Feb 6, 2023 07:01AM LAVA Therapeutics (LVTX) Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
Feb 6, 2023 07:00AM LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer
Jan 23, 2023 07:00AM LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium
Jan 6, 2023 01:17PM LAVA Therapeutics (LVTX) Names Peter A. Kiener, Mary Wadlinger to board
Jan 6, 2023 01:07PM LAVA Therapeutics Announces Appointment of New Directors to the Board
Jan 3, 2023 07:00AM LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 10, 2022 10:00AM LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 16, 2022 04:05PM LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
Nov 3, 2022 04:05PM LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
Nov 3, 2022 09:00AM LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 1, 2022 07:03AM LAVA Therapeutics (LVTX) Appoints Fred M. Powell as CFO
Nov 1, 2022 07:00AM LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
Oct 7, 2022 11:00AM LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Sep 26, 2022 08:02AM Seagen (SGEN), LAVA Therapeutics (LVTX) Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 13, 2022 04:05PM LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Sep 7, 2022 07:41AM LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Jun 16, 2022 04:09PM LAVA Therapeutics (LVTX) Highlights Encouraging Clinical Updates on LAVA-051
Jun 16, 2022 04:05PM LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients
Jun 15, 2022 07:02AM LAVA Therapeutics (LVTX) Appoints James Noble and Jay Backstrom to its Board
Jun 15, 2022 07:00AM LAVA Therapeutics Announces Two Appointments to its Board of Directors
Jun 2, 2022 07:00AM LAVA Therapeutics to Participate at the Jefferies Healthcare Conference
Jun 1, 2022 07:00AM LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical O
May 31, 2022 04:05PM LAVA Therapeutics Announces Annual Meeting of Shareholders
May 17, 2022 07:00AM LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
May 12, 2022 07:01AM LAVA Therapeutics (LVTX) Announces FDA IND Clearance of LAVA-051
May 12, 2022 07:00AM LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies
May 5, 2022 07:00AM LAVA Therapeutics to Participate at the UBS Global Healthcare Conference
Apr 27, 2022 10:05AM LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Mar 24, 2022 06:31AM LAVA Therapeutics (LVTX) Reports Q4, Provides Business Update
Mar 24, 2022 06:30AM LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
Mar 10, 2022 06:30AM LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022
Mar 7, 2022 08:35AM LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
Feb 1, 2022 06:30AM LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
Jan 28, 2022 07:00AM Lava Therapeutics Announces Participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022
Jan 18, 2022 08:30AM LAVA Therapeutics Presents Preclinical Data on its Gammabody™ T Cell Engager Platform at the 21st Annual PepTalk Conference
Dec 20, 2021 10:06AM CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 10:06AM CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
Dec 20, 2021 07:00AM LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories